We are live on ! Find out more
GLMD icon

Galmed Pharmaceuticals
GLMD

17 hedge funds and large institutions have $878K invested in Galmed Pharmaceuticals in 2023 Q1 according to their latest regulatory filings, with 3 funds opening new positions, 1 increasing their positions, 4 reducing their positions, and 5 closing their positions.

New
Increased
Maintained
Reduced
Closed

0% less ownership

Funds ownership: 0.01% → 0.01% (-0%)

11% less funds holding

Funds holding: 19 → 17 (-2)

28% less capital invested

Capital invested by funds: $1.21M → $878K (-$336K)

40% less first-time investments, than exits

New positions opened: 3 | Existing positions closed: 5

75% less repeat investments, than reductions

Existing positions increased: 1 | Existing positions reduced: 4

Holders
17
Holders Change
-2
Holders Change %
-10.53%
% of All Funds
0.27%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
1
Reduced
4
Closed
5
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–

Top Buyers

Rank Fund Capital Flow
1
Citadel Advisors
Citadel Advisors
Florida
+$24K
2
VF
Virtu Financial
New York
+$18.9K
3
Morgan Stanley
Morgan Stanley
New York
+$13.7K
4
BNP Paribas Financial Markets
BNP Paribas Financial Markets
France
+$8.59K

Top Sellers

Rank Fund Capital Flow
1
BI
BVF Inc
California
-$234K
2
Millennium Management
Millennium Management
New York
-$11.2K
3
UBS Group
UBS Group
Switzerland
-$10.3K
4
Jane Street
Jane Street
New York
-$8.59K
5
SG
StoneX Group
New York
-$5.28K

GLMD Hedge Fund Activity: Q1 2023 in Review

17 of the 6,283 institutional investors tracked by Wall St. Rank reported a position in Galmed Pharmaceuticals (GLMD) for Q1 2023, worth a combined $878K — down 28% from $1.21M a quarter earlier.

Sellers outnumbered buyers: 5 funds closed out of GLMD and 3 opened new positions — a net loss of 2 holders — while 4 trimmed existing stakes and 1 added.

The largest buyer was Citadel Advisors, opening a new position worth an estimated $24K. The largest seller was BVF Inc, cutting an estimated $234K.

  • 17 institutional investors held Galmed Pharmaceuticals (GLMD) as of Q1 2023, down from 19 in Q4 2022.
  • Funds reported $878K of Galmed Pharmaceuticals stock for Q1 2023, down 28% quarter-over-quarter.
  • 3 funds opened new Galmed Pharmaceuticals positions in Q1 2023 and 5 closed out, a net change of -2 holders.
  • The largest Galmed Pharmaceuticals buyer in Q1 2023 was Citadel Advisors, an estimated $24K added.
  • The largest Galmed Pharmaceuticals seller in Q1 2023 was BVF Inc, an estimated $234K sold.

Based on aggregated 13F filings for Q1 2023.